Unassociated Document
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
_______________________________
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
 
SECURITIES EXCHANGE ACT OF 1934
 
 
Date of report (Date of earliest event reported): August 21, 2008
 
Immunomedics, Inc.
 
(Exact Name of Registrant as Specified in Charter)

Delaware  000-12104    61-1009366
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

                                                          
 
 300 American Road, Morris Plains, New Jersey
07950
(Address of Principal Executive Offices)
(Zip Code)

(973) 605-8200
(Registrant's telephone number,
including area code)

 
                                            Not applicable                                            
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17 CFR 240.13e-4(c)).
 
 
Item 8.01.                                           Other Events.
 
On August 15, 2008, Immunomedics, Inc., a Delaware corporation (the “Company”), received notice from the Premerger Office of the Federal Trade Commission that early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) has been granted for the License and Collaboration Agreement (the “Agreement”) that the Company had entered into with Nycomed GmbH (“Nycomed”) providing Nycomed a worldwide license to develop, manufacture and commercialize veltuzumab, the Company’s humanized anti-CD20 antibody in the subcutaneous formulation, for the treatment of all non-cancer indications.  The Agreement became effective upon termination of the HSR required waiting period.
 
On August 21, 2008, the Company received a non-refundable initial cash payment of $40 million from Nycomed in accordance with the terms of the Agreement.  With receipt of the $40 million, the Company will terminate the $9.0 million revolving line of credit it has secured from Bank of America, N.A., pursuant to a loan agreement, effective June 9, 2008 (the “Credit Facility”).  Currently, the Company has no amounts outstanding under the Credit Facility.
 

 
 
 

SIGNATURES
 


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
IMMUNOMEDICS, INC.



By: /s/ Cynthia Sullivan
Name:Cynthia Sullivan
Title:President and Chief Executive Officer


Date:  August 21, 2008